MRX-6
Small molecule
MRX-6 is one of 18 small molecule programs targeting Contact Dermatitis. It is currently in development.
1
Indications
2
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Contact Dermatitis
#DrugCompanyPhaseTrials
1Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Decadron
AAspen Global Incorporated
Approved
Stelara
Johnson & JohnsonPhase 3
Ilaris
NovartisPhase 3
Tremfya
Johnson & JohnsonPhase 3
Flovent
GSKPhase 3
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Humira
CCelltrion
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MRX-6. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- CCelsus Therapeutics PLC